Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Recruiting now · Phase 1
Conditions studied: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
In brief
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Key facts
- Study ID
- NCT06966024
- Run by
- Deciphera Pharmaceuticals, LLC
- People needed
- 60
- Starts
- 2025-08-27
- Expected to finish
- 2029-02-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- Vanderbilt- Ingram Cancer Center — Nashville, Tennessee, United States (enrolling)
- NEXT Oncology, Austin — Austin, Texas, United States (enrolling)
- NEXT Oncology, San Antonio — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.